Young women with breast cancer: how many are actually candidates for fertility preservation?

Arch Gynecol Obstet. 2012 Dec;286(6):1521-7. doi: 10.1007/s00404-012-2457-5. Epub 2012 Jul 21.

Abstract

Purpose: There are no data regarding the actual need for fertility preservation (FP) in breast cancer (BC) patients. Our study provides a practical needs assessment for reproductive medicine by analyzing an unselected cohort of young BC patients. This assessment considers oncological factors as well as the patient's obstetrical and gynecological history and reproductive outcome after BC diagnosis. We aimed to identify how many patients are actually potential candidates for FP and how many patients might consequently use their cryopreserved gametes to achieve pregnancy.

Methods: Based on a prospective BC database, we analyzed all patients who were ≤40 years at initial diagnosis (time period of diagnosis: 1990-2007; n=100; 7.7% of the entire BC cohort; median age: 35.9 years).

Results: Using an algorithm of exclusion criteria considering disease-specific, therapy-specific and family history characteristics, 36 patients who received chemotherapy were identified as potential "classical" candidates for FP. After 5 years, 22 women were identified as potential candidates for using their cryopreserved gametes to achieve pregnancy; the majority of these patients were childless (n=16, 72.7%) and in their late reproductive years (n=12, 54.5%).

Conclusions: Our study demonstrates that in a cohort of young BC patients only a minority of women are candidates for FP. Young BC patients who wish to have children in the future usually carry risk factors both from oncological and reproductive medicine perspective. Due to this high-risk profile, the rarity of BC in young age and the limited number of patients who might actually have opted for FP, these women must be offered timely and multidisciplinary counseling in highly specialized centers.

MeSH terms

  • Adult
  • Algorithms
  • Antineoplastic Agents / adverse effects
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Cryopreservation*
  • Family Characteristics
  • Female
  • Fertility Preservation*
  • Germ Cells*
  • Hormones / adverse effects
  • Humans
  • Needs Assessment*
  • Patient Selection
  • Retrospective Studies
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Hormones